Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMBQYE)

Drug Name
carbacyclin Drug Info
Synonyms carboprostacyclin
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311242
TTD Drug ID
DMMBQYE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AS-013 DMD7XWS Thrombosis DB61-GB90 Phase 3 [4]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [5]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [6]
ZD6416 DM46JIR Pain MG30-MG3Z Discontinued in Phase 2 [7]
ONO-8130 DMBDCL4 Pollakiuria MF50.1 Terminated [8]
ONO-8711 DM2VRK7 Pain MG30-MG3Z Terminated [9]
U46619 DM13FX4 Discovery agent N.A. Investigative [5]
PGD2 DMYDW6J Discovery agent N.A. Investigative [10]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [3]
cicaprost DM7ZJ4H Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [3]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [11]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [12]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [13]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [14]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
E7046 DMFVT43 Rectal adenocarcinoma 2B92 Phase 1 [16]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [17]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [19]
Alprostadil DMWH7NQ Aorta coarctation Approved [20]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [21]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [22]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [23]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [3]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [24]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [25]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [23]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [26]
QAW-039 DMPCFXN Asthma CA23 Phase 3 [27]
AMG 853 DM973N4 Asthma CA23 Phase 2 [28]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [29]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [30]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [31]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [32]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [33]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [35]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [36]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [37]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [38]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [39]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [23]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [40]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [41]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alprostadil DMWH7NQ Aorta coarctation Approved [43]
Ridogrel DMWH9CN Acute myocardial infarction BA41 Approved [44]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [23]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [45]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [46]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [47]
TAK-128 DMHPEFS Diabetic neuropathy 8C0Z Phase 2 [48]
Ifetroban sodium DMZP84Y Thrombosis DB61-GB90 Phase 2 [49]
Ifetroban DMEV39E Aspirin-induced asthma CA23.20 Phase 2 [50]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [3]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [41]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [3]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [6]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [52]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [53]
U46619 DM13FX4 Discovery agent N.A. Investigative [2]
PGD2 DMYDW6J Discovery agent N.A. Investigative [5]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [2]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostacyclin receptor (PTGIR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Treprostinil DMTIQF3 Pulmonary arterial hypertension BB01.0 Approved [54]
Selexipag DMAHSU0 Pulmonary arterial hypertension BB01.0 Approved [55]
Epoprostenol DMUTYR2 Allergic rhinitis CA08.0 Approved [56]
Dinoprost Tromethamine DMXQKSL Abortion JA00 Approved [57]
Misoprostol DMHVJFK Medical abortion JA00.1Z Approved [57]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [23]
Beraprost DML634R Pulmonary hypertension BB01 Phase 4 [58]
esuberaprost DMXLGED Gout FA25 Phase 3 [59]
Ralinepag DM7G4Y9 Pulmonary arterial hypertension BB01.0 Phase 2 [60]
Clinprost DM6E5VA Asthma CA23 Discontinued in Preregistration [61]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostacyclin receptor (PTGIR) TTOFYT1 PI2R_HUMAN Agonist [2]
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Agonist [2]
Prostaglandin E2 receptor EP1 (PTGER1) TTG1QMU PE2R1_HUMAN Agonist [2]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Agonist [2]
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Agonist [3]
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Agonist [3]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Agonist [2]
Thromboxane A2 receptor (TBXA2R) TT2O84V TA2R_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1893).
2 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
3 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
4 Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
5 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
6 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
7 The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
8 ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
9 Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
10 Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
11 Clinical pipeline report, company report or official report of Avarx.
12 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
13 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
14 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
15 Clinical pipeline report, company report or official report of Tempest Therapeutics.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
18 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
20 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
21 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
22 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
23 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
24 Pfizer. Product Development Pipeline. March 31 2009.
25 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
28 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
29 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
30 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
31 Clinical pipeline report, company report or official report of Shionogi (2011).
32 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
33 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
34 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
35 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
36 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
37 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
38 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
39 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
40 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
41 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
42 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
43 Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
44 Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
45 Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
46 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
47 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
48 ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
49 AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
50 Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
51 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
52 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
53 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
54 Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
55 Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
56 Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
57 Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
58 Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
59 Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
60 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
61 Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.